JP6871866B2 - 抗ｒｈｏ ｇｔｐａｓｅコンホーメーションシングルドメイン抗体及びその使用 - Google Patents

抗ｒｈｏ ｇｔｐａｓｅコンホーメーションシングルドメイン抗体及びその使用 Download PDF

Info

Publication number
JP6871866B2
JP6871866B2 JP2017558784A JP2017558784A JP6871866B2 JP 6871866 B2 JP6871866 B2 JP 6871866B2 JP 2017558784 A JP2017558784 A JP 2017558784A JP 2017558784 A JP2017558784 A JP 2017558784A JP 6871866 B2 JP6871866 B2 JP 6871866B2
Authority
JP
Japan
Prior art keywords
cell
single domain
domain antibody
cells
cancer
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2017558784A
Other languages
English (en)
Japanese (ja)
Other versions
JP2018506302A (ja
JP2018506302A5 (enExample
Inventor
オリション，オーレリアン
ケラー，ローラ
ファーヴ，ジル
ベリー，ニコラ
チネストラ，パトリック
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
INSTITUT CLAUDIUS REGAUD
Original Assignee
INSTITUT CLAUDIUS REGAUD
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by INSTITUT CLAUDIUS REGAUD filed Critical INSTITUT CLAUDIUS REGAUD
Publication of JP2018506302A publication Critical patent/JP2018506302A/ja
Publication of JP2018506302A5 publication Critical patent/JP2018506302A5/ja
Application granted granted Critical
Publication of JP6871866B2 publication Critical patent/JP6871866B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/40—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/573—Immunoassay; Biospecific binding assay; Materials therefor for enzymes or isoenzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/22—Immunoglobulins specific features characterized by taxonomic origin from camelids, e.g. camel, llama or dromedary
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/567—Framework region [FR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/569—Single domain, e.g. dAb, sdAb, VHH, VNAR or nanobody®
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/80—Immunoglobulins specific features remaining in the (producing) cell, i.e. intracellular antibodies or intrabodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/80—Immunoglobulins specific features remaining in the (producing) cell, i.e. intracellular antibodies or intrabodies
    • C07K2317/82—Immunoglobulins specific features remaining in the (producing) cell, i.e. intracellular antibodies or intrabodies functional in the cytoplasm, the inner aspect of the cell membrane, the nucleus or the mitochondria
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/95—Fusion polypeptide containing a motif/fusion for degradation (ubiquitin fusions, PEST sequence)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/8509—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells for producing genetically modified animals, e.g. transgenic
    • C12N2015/8518—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells for producing genetically modified animals, e.g. transgenic expressing industrially exogenous proteins, e.g. for pharmaceutical use, human insulin, blood factors, immunoglobulins, pseudoparticles

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Immunology (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Biomedical Technology (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • Hematology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Physics & Mathematics (AREA)
  • Virology (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Urology & Nephrology (AREA)
  • Plant Pathology (AREA)
  • Food Science & Technology (AREA)
  • Cell Biology (AREA)
  • Analytical Chemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Oncology (AREA)
  • Peptides Or Proteins (AREA)
JP2017558784A 2015-02-03 2016-02-02 抗ｒｈｏ ｇｔｐａｓｅコンホーメーションシングルドメイン抗体及びその使用 Active JP6871866B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP15305160 2015-02-03
EP15305160.2 2015-02-03
PCT/EP2016/052136 WO2016124568A1 (en) 2015-02-03 2016-02-02 Anti-rho gtpase conformational single domain antibodies and uses thereof

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2020096921A Division JP7095019B2 (ja) 2015-02-03 2020-06-03 抗ｒｈｏ ｇｔｐａｓｅコンホーメーションシングルドメイン抗体及びその使用

Publications (3)

Publication Number Publication Date
JP2018506302A JP2018506302A (ja) 2018-03-08
JP2018506302A5 JP2018506302A5 (enExample) 2018-12-27
JP6871866B2 true JP6871866B2 (ja) 2021-05-19

Family

ID=52464303

Family Applications (3)

Application Number Title Priority Date Filing Date
JP2017558784A Active JP6871866B2 (ja) 2015-02-03 2016-02-02 抗ｒｈｏ ｇｔｐａｓｅコンホーメーションシングルドメイン抗体及びその使用
JP2020096921A Active JP7095019B2 (ja) 2015-02-03 2020-06-03 抗ｒｈｏ ｇｔｐａｓｅコンホーメーションシングルドメイン抗体及びその使用
JP2022100217A Pending JP2022130514A (ja) 2015-02-03 2022-06-22 抗ｒｈｏ ｇｔｐａｓｅコンホーメーションシングルドメイン抗体及びその使用

Family Applications After (2)

Application Number Title Priority Date Filing Date
JP2020096921A Active JP7095019B2 (ja) 2015-02-03 2020-06-03 抗ｒｈｏ ｇｔｐａｓｅコンホーメーションシングルドメイン抗体及びその使用
JP2022100217A Pending JP2022130514A (ja) 2015-02-03 2022-06-22 抗ｒｈｏ ｇｔｐａｓｅコンホーメーションシングルドメイン抗体及びその使用

Country Status (5)

Country Link
US (3) US10544210B2 (enExample)
EP (1) EP3253791A1 (enExample)
JP (3) JP6871866B2 (enExample)
CN (2) CN114133450B (enExample)
WO (1) WO2016124568A1 (enExample)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10544210B2 (en) * 2015-02-03 2020-01-28 Inserm (Institut National De La Sante Et De La Recherche Medicale) Anti-Rho GTPase conformational single domain antibodies and uses thereof
JP7538532B2 (ja) * 2018-10-17 2024-08-22 国立大学法人 東京大学 ペプチドライブラリーの製造方法
WO2020219407A1 (en) * 2019-04-22 2020-10-29 University Of Washington Chemically induced protein dimerization systems
US20220259295A1 (en) * 2019-06-20 2022-08-18 INSERM (Institut National de la Santé et de la Recherche Médicale) Method useful in tolerance induction therapy and kits therefore
WO2021078359A1 (en) * 2019-10-21 2021-04-29 INSERM (Institut National de la Santé et de la Recherche Médicale) Use of inhibitors of cubilin for the treatment of chronic kidney diseases
GB202005876D0 (en) * 2020-04-22 2020-06-03 Univ Dundee Protein degradation
CN114736302B (zh) * 2022-05-12 2022-10-25 诺赛联合(北京)生物医学科技有限公司 一种干细胞无血清培养基
CN114605554B (zh) * 2022-05-12 2022-07-05 诺赛联合(北京)生物医学科技有限公司 一种间充质干细胞培养基

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2919890B2 (ja) 1988-11-11 1999-07-19 メディカル リサーチ カウンスル 単一ドメインリガンド、そのリガンドからなる受容体、その製造方法、ならびにそのリガンドおよび受容体の使用
DE69330523T4 (de) 1992-08-21 2012-08-23 Vrije Universiteit Brussel Immunoglobuline ohne leichte ketten
EP0739981A1 (en) 1995-04-25 1996-10-30 Vrije Universiteit Brussel Variable fragments of immunoglobulins - use for therapeutic or veterinary purposes
US6013516A (en) 1995-10-06 2000-01-11 The Salk Institute For Biological Studies Vector and method of use for nucleic acid delivery to non-dividing cells
US5994136A (en) 1997-12-12 1999-11-30 Cell Genesys, Inc. Method and means for producing high titer, safe, recombinant lentivirus vectors
JP2002507410A (ja) 1998-03-27 2002-03-12 プロルーム・リミテッド ルシフェラーゼ、蛍光タンパク質、ルシフェラーゼおよび蛍光タンパク質をコードする核酸および、診断、高処理スクリーニングおよび新規アイテムにおけるその使用
US20060073141A1 (en) 2001-06-28 2006-04-06 Domantis Limited Compositions and methods for treating inflammatory disorders
US7563443B2 (en) 2004-09-17 2009-07-21 Domantis Limited Monovalent anti-CD40L antibody polypeptides and compositions thereof
US20090208446A1 (en) * 2006-05-12 2009-08-20 The Queen's University Of Belfast DUB3 as a Cancer Therapy Target
EP2287197A1 (en) * 2009-08-21 2011-02-23 Pierre Fabre Medicament Anti-cMET antibody and its use for the detection and the diagnosis of cancer
CN102399288B (zh) * 2011-10-19 2013-06-05 山西德丰信成生物科技有限公司 针对免疫球蛋白Fc段的单域重链抗体
WO2014195713A1 (en) * 2013-06-06 2014-12-11 David J Rowlands Single domain antibody display
US10544210B2 (en) * 2015-02-03 2020-01-28 Inserm (Institut National De La Sante Et De La Recherche Medicale) Anti-Rho GTPase conformational single domain antibodies and uses thereof

Also Published As

Publication number Publication date
US20220213221A1 (en) 2022-07-07
JP2018506302A (ja) 2018-03-08
EP3253791A1 (en) 2017-12-13
JP7095019B2 (ja) 2022-07-04
US10544210B2 (en) 2020-01-28
US11319381B2 (en) 2022-05-03
CN107531780A (zh) 2018-01-02
CN114133450B (zh) 2023-09-22
US20210171658A1 (en) 2021-06-10
JP2020156498A (ja) 2020-10-01
CN107531780B (zh) 2021-11-02
CN114133450A (zh) 2022-03-04
JP2022130514A (ja) 2022-09-06
WO2016124568A1 (en) 2016-08-11
US20180022794A1 (en) 2018-01-25

Similar Documents

Publication Publication Date Title
JP7095019B2 (ja) 抗ｒｈｏ ｇｔｐａｓｅコンホーメーションシングルドメイン抗体及びその使用
CN109310756A (zh) 新型血管生成素2，vegf双特异性拮抗剂
Kabayama et al. An ultra-stable cytoplasmic antibody engineered for in vivo applications
EP2697255A2 (en) Agonists and antagonists of the wnt pathway
US20180118818A1 (en) Sensor systems for target ligands and uses thereof
CN107249636A (zh) 以ckap4作为靶分子的抗肿瘤剂
JP2002540814A (ja) 転移性前立腺腫瘍の診断および処置のための方法
WO2014106639A1 (en) Intracellular phenotypic screening
JP7162897B2 (ja) 融合タンパク質
JP2013542720A (ja) 抗エフリン−ｂ２抗体およびその使用
CN111378040B (zh) 检测多种恶性肿瘤细胞的抗体及其应用
SG181113A1 (en) Treatment and prevention of cancers associated with intracellular oncoproteins by antibody therapy or vaccination
US20240317867A1 (en) Igfr-like 2 receptor and uses thereof
RU2846293C1 (ru) АНТИТЕЛО К EphA4
Keller et al. downstream signaling
US11174322B2 (en) Antibodies and peptides to treat HCMV related diseases
KR101254243B1 (ko) ｃｈｋ１ 단백질 및 ＨＪＵＲＰ 단백질 간의 상호작용을 억제하는 펩티드, 이를 포함하는 항암제 및 항암제를 스크리닝하는 방법
CN109890844A (zh) 抗ninj-1抗体及其用途
Juhász Murine CD248 and its cytoplasmic domain: characterising a novel tumour and inflammation marker
WO2015110707A1 (en) Methods and uses related to adamts3

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20181113

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20181113

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20191023

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20191127

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20200204

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20200603

C60 Trial request (containing other claim documents, opposition documents)

Free format text: JAPANESE INTERMEDIATE CODE: C60

Effective date: 20200603

C11 Written invitation by the commissioner to file amendments

Free format text: JAPANESE INTERMEDIATE CODE: C11

Effective date: 20200616

A911 Transfer to examiner for re-examination before appeal (zenchi)

Free format text: JAPANESE INTERMEDIATE CODE: A911

Effective date: 20200901

C21 Notice of transfer of a case for reconsideration by examiners before appeal proceedings

Free format text: JAPANESE INTERMEDIATE CODE: C21

Effective date: 20200908

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20201104

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20210204

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20210330

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20210416

R150 Certificate of patent or registration of utility model

Ref document number: 6871866

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250